Developer docs
API playgroundTry for free, no card

Search company profiles

Mabylon

Full company profile

uuid0000bho

Namestring
Mabylon
Legal namestring
Mabylon AG
Websiteurl
mabylon.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Mabylon AG is a clinical-stage Swiss biotechnology company founded in 2015 as a spinout from ImmunoQure and headquartered in Schlieren, Zürich. It discovers and engineers novel antibody therapeutics in three therapeutic areas: severe allergies (food and pollen), inflammatory diseases (notably inflammatory bowel disease and neuroinflammation), and neurology (ALS and frontotemporal dementia). Its lead asset, MY006, is a trispecific anti-peanut antibody currently in Phase I clinical development (Phase Ia completed with favorable safety and pharmacokinetic profiles, Phase Ib initiated as of May 2026), offering a prophylactic passive-immunization approach with only a few subcutaneous injections per year.

The company's core technology is a proprietary human-derived antibody discovery platform that combines single-cell B-cell screening with high-throughput antibody-expression workflows to identify and clone natural B-cell-derived monoclonal antibodies within two to three weeks, followed by functional assays and engineering to produce multispecific therapeutics such as the trispecific MY006. Its broader pipeline includes MY010 (multispecific antibody against birch and related tree/fruit/nut allergens, preclinical), MY011 (cross-reactive grass pollen antibody, preclinical), MY001 (TDP-43 intrabody for ALS/FTD, preclinical), and MY012 (anti-ASC inflammasome antibody for IBD/neuroinflammation, preclinical). The platform is supported by Clinical Development Advisory Boards in food and pollen allergies drawing on clinicians and researchers from institutions including Mass General, Harvard, University of Bonn, and Novartis.

Mabylon is pre-revenue and pursues an enterprise partnership and licensing model rather than direct commercialization. Strategic relationships include Pfizer (via Pfizer Ignite for CMC and IND-enabling work on MY006), SciNeuro Pharmaceuticals (collaboration and license agreement for ALS/FTLD antibody therapeutics), and a broad base of academic and grant partners (Innosuisse, Target ALS, ALS Association, NIH, EU Horizon 2020, Eurostars). Capital is sourced primarily from private investors, with a CHF 30 million round closed in August 2025 led by former Roche management and board members to advance MY006 through Phase Ia/b and expand discovery and preclinical programs.

Short descriptiontext

Mabylon AG is a clinical-stage Swiss biotechnology company that discovers and develops human-derived, multispecific antibody therapeutics for severe allergies, inflammatory bowel disease, and neurodegenerative disorders including ALS, using a proprietary single-cell B-cell screening platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, biopharmaceuticals development, allergy immunotherapy, human-derived antibodies, multi-specific antibodies
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / Antibody Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic antibody development and licensing
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotechnology company developing antibody therapeutics for allergies, inflammation, and neurology with pipeline programs in clinical and preclinical stages. Revenue expected through licensing deals, co-development partnerships, and eventual product commercialization.

mabylon.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mabylon AG is a clinical-stage biotechnology company that discovers and engineers novel antibody therapeutics for allergies, inflammation, and neurological disorders. The company leverages a proprietary human-derived antibody discovery platform using B-cell screening and high-throughput expression to identify and clone monoclonal antibodies within two to three weeks, and develops these into multi-specific therapeutic candidates (MY006, MY010, MY011, MY001, MY012). The company advances candidates through clinical development in collaboration with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • MY006 Phase Ia completed with favorable safety and pharmacokinetic profiles; Safety Monitoring Committee recommended Phase Ib initiation
+1 more record
Product overview1 text field

Mabylon AG is a clinical-stage biotechnology company with an antibody discovery technology platform that leverages human-derived antibodies from patients' immune repertoires to develop multi-specific therapeutics. The company's pipeline consists of multiple antibody programs: MY006 (tri-specific anti-peanut antibody in Phase I for peanut allergy), MY010 (birch pollen antibody in pre-clinical), MY011 (grass pollen antibody in pre-clinical), MY001 (TDP-43 intrabody for ALS in pre-clinical), and MY012 (anti-ASC antibody for IBD/neuroinflammation in pre-clinical). The technology platform enables rapid identification and cloning of B-cell-derived antibodies for development into monoclonal or multi-specific antibody therapies.

Product and service5 records
1MY006
CategoryCore product (allergy immunotherapy)
Description

A tri-specific antibody for the prophylactic treatment of peanut allergy that binds critical allergenic epitopes to neutralize major peanut allergens and prevent anaphylaxis, designed to provide protection with only a few subcutaneous injections per year. Currently in Phase I clinical trials (Phase Ia completed with favorable safety and pharmacokinetic profiles; Phase Ib initiated).

2MY010
CategoryCore product (allergy immunotherapy)
Description

A multispecific and cross-reactive antibody targeting the birch pollen allergen Bet v 1 as well as major birch-related tree, fruit and nut allergens, designed to provide superior protection with only one injection pre-season. Currently in pre-clinical development entering CMC and IND-enabling studies.

3MY011
CategoryCore product (allergy immunotherapy)
Description

A broadly cross-reactive antibody-based therapeutic designed to neutralize major grass pollen allergens from timothy, rye, and velvet grass, providing rapid and durable protection throughout the season after single administration. Currently advancing through pre-clinical development.

4MY001
CategoryCore product (neurology)
Description

Human-derived TDP-43 intrabodies designed to restore normal TDP-43 function by reducing pathological TDP-43 aggregates in diseased neurons, aiming to halt disease progression in amyotrophic lateral sclerosis (ALS). Currently at pre-clinical stages.

5MY012
CategoryCore product (inflammation)
Description

An anti-ASC antibody targeting ASC, a crucial component of the inflammasome expressed by innate immune cells, to inhibit the propagation of inflammation triggered by ASC specks. Potential applications in inflammatory bowel disease (IBD) and neuroinflammation. Currently at pre-clinical stages.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

SciNeuro and Mabylon announced a Collaboration and License Agreement for the development of immunotherapy to fight ALS and FTLD (frontotemporal dementia), combining Mabylon's antibody expertise with SciNeuro's neurological disease focus.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

For CMC and IND-enabling studies of the lead program MY006, Mabylon has collaborated with Pfizer through the Pfizer Ignite offering, an end-to-end service for selected biotech companies. This allowed Mabylon to leverage Pfizer's extensive therapeutic development expertise to speed the progression of the peanut allergy program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss privately held biotech developing multi-specific antibody therapeutics; highly comparable as a fellow Schlieren/Zürich-area multi-specific antibody company whose lead asset (NM26) was acquired by J&J for $1.25B in 2024 — Mabylon's CMO Peter Lichtlen co-founded Numab.

TypeBroad incumbent
Description

Late-stage immunology biotech developing antibody therapeutics for autoimmune diseases (e.g., VYVGART); comparable as a clinically validated antibody-focused immunology company and potential future competitor in allergy/inflammation.

TypeEmerging player
Description

Swedish clinical-stage antibody biotech with a proprietary discovery platform targeting immuno-oncology and autoimmune diseases; comparable as an emerging clinical-stage antibody platform player, and Board member Thomas Hecht sits on BioInvent's board.

4UCB Pharma
TypeBroad incumbent
Description

Global biopharma with a major focus on immunology/autoimmune and neurology antibody therapeutics; Mabylon's CSO Niccolò Pengo previously worked on antibody therapeutics discovery at UCB.

TypeBroad incumbent
Description

Global leader in monoclonal antibody therapeutics and immunology; highly relevant comparator given Mabylon's deep Roche DNA (Chairman Keller and Board member Haenggi are former Roche executives, and investors include former Roche management).

TypeBroad incumbent
Description

Clinical-stage immunology company leveraging human-derived antibody platforms (acquired HUMABS BioMed, Mabylon CEO's former company); comparable for its antibody platform approach and immunology focus, but operates at much larger scale.

TypeBroad incumbent
Description

Large-cap biopharma with deep antibody discovery capabilities (VelocImmune platform) and marketed immunology assets (Dupixent); a relevant incumbent comparator for antibody platform reach and commercial scale in immunology.

TypeEmerging player
Description

Clinical-stage biotech developing engineered allergen-specific IgG antibodies for food allergies; directly comparable as a passive-immunization antibody competitor in the peanut/food allergy space where Mabylon's MY006 is positioned.

TypeEmerging player
Description

Clinical-stage immunology biotech developing Nanobody® therapeutics for inflammatory diseases (e.g., hidradenitis suppurativa, psoriatic arthritis); comparable as a publicly listed emerging immunology-focused antibody developer.

TypeEmerging player
Description

Clinical-stage biotech developing antibody therapeutics for respiratory and inflammatory diseases (formerly focused on severe asthma); comparable as an emerging antibody player in the I&I space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mabylon

Biopharmaceuticals / Antibody Therapeuticsmabylon.com

Mabylon AG is a clinical-stage Swiss biotechnology company that discovers and develops human-derived, multispecific antibody therapeutics for severe allergies, inflammatory bowel disease, and neurodegenerative disorders including ALS, using a proprietary single-cell B-cell screening platform.

What Mabylon does

Mabylon AG is a clinical-stage Swiss biotechnology company founded in 2015 as a spinout from ImmunoQure and headquartered in Schlieren, Zürich. It discovers and engineers novel antibody therapeutics in three therapeutic areas: severe allergies (food and pollen), inflammatory diseases (notably inflammatory bowel disease and neuroinflammation), and neurology (ALS and frontotemporal dementia). Its lead asset, MY006, is a trispecific anti-peanut antibody currently in Phase I clinical development (Phase Ia completed with favorable safety and pharmacokinetic profiles, Phase Ib initiated as of May 2026), offering a prophylactic passive-immunization approach with only a few subcutaneous injections per year.

The company's core technology is a proprietary human-derived antibody discovery platform that combines single-cell B-cell screening with high-throughput antibody-expression workflows to identify and clone natural B-cell-derived monoclonal antibodies within two to three weeks, followed by functional assays and engineering to produce multispecific therapeutics such as the trispecific MY006. Its broader pipeline includes MY010 (multispecific antibody against birch and related tree/fruit/nut allergens, preclinical), MY011 (cross-reactive grass pollen antibody, preclinical), MY001 (TDP-43 intrabody for ALS/FTD, preclinical), and MY012 (anti-ASC inflammasome antibody for IBD/neuroinflammation, preclinical). The platform is supported by Clinical Development Advisory Boards in food and pollen allergies drawing on clinicians and researchers from institutions including Mass General, Harvard, University of Bonn, and Novartis.

Mabylon is pre-revenue and pursues an enterprise partnership and licensing model rather than direct commercialization. Strategic relationships include Pfizer (via Pfizer Ignite for CMC and IND-enabling work on MY006), SciNeuro Pharmaceuticals (collaboration and license agreement for ALS/FTLD antibody therapeutics), and a broad base of academic and grant partners (Innosuisse, Target ALS, ALS Association, NIH, EU Horizon 2020, Eurostars). Capital is sourced primarily from private investors, with a CHF 30 million round closed in August 2025 led by former Roche management and board members to advance MY006 through Phase Ia/b and expand discovery and preclinical programs.

Mabylon firmographics

Firmographics
Name
Mabylon
Legal name
Mabylon AG
Website
https://mabylon.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Mabylon AG is a clinical-stage Swiss biotechnology company that discovers and develops human-derived, multispecific antibody therapeutics for severe allergies, inflammatory bowel disease, and neurodegenerative disorders including ALS, using a proprietary single-cell B-cell screening platform.
Ownership category
akta.pro rank

Mabylon industry classification

Industry
Product category
Biopharmaceuticals / Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody therapeutics
  • Biopharmaceuticals development
  • Allergy immunotherapy
  • Human-derived antibodies
  • Multi-specific antibodies

Where Mabylon is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Mabylon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Therapeutic antibody development and licensing: Pre-revenue clinical-stage biotechnology company developing antibody therapeutics for allergies, inflammation, and neurology with pipeline programs in clinical and preclinical stages. Revenue expected through licensing deals, co-development partnerships, and eventual product commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Mabylon product offering

Product offering

Core offering

Mabylon AG is a clinical-stage biotechnology company that discovers and engineers novel antibody therapeutics for allergies, inflammation, and neurological disorders. The company leverages a proprietary human-derived antibody discovery platform using B-cell screening and high-throughput expression to identify and clone monoclonal antibodies within two to three weeks, and develops these into multi-specific therapeutic candidates (MY006, MY010, MY011, MY001, MY012). The company advances candidates through clinical development in collaboration with pharmaceutical partners.

Product overview

Mabylon AG is a clinical-stage biotechnology company with an antibody discovery technology platform that leverages human-derived antibodies from patients' immune repertoires to develop multi-specific therapeutics. The company's pipeline consists of multiple antibody programs: MY006 (tri-specific anti-peanut antibody in Phase I for peanut allergy), MY010 (birch pollen antibody in pre-clinical), MY011 (grass pollen antibody in pre-clinical), MY001 (TDP-43 intrabody for ALS in pre-clinical), and MY012 (anti-ASC antibody for IBD/neuroinflammation in pre-clinical). The technology platform enables rapid identification and cloning of B-cell-derived antibodies for development into monoclonal or multi-specific antibody therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • MY006 A tri-specific antibody for the prophylactic treatment of peanut allergy that binds critical allergenic epitopes to neutralize major peanut allergens and prevent anaphylaxis, designed to provide protection with only a few subcutaneous injections per year. Currently in Phase I clinical trials (Phase Ia completed with favorable safety and pharmacokinetic profiles; Phase Ib initiated).
  • MY010 A multispecific and cross-reactive antibody targeting the birch pollen allergen Bet v 1 as well as major birch-related tree, fruit and nut allergens, designed to provide superior protection with only one injection pre-season. Currently in pre-clinical development entering CMC and IND-enabling studies.
  • MY011 A broadly cross-reactive antibody-based therapeutic designed to neutralize major grass pollen allergens from timothy, rye, and velvet grass, providing rapid and durable protection throughout the season after single administration. Currently advancing through pre-clinical development.
  • MY001 Human-derived TDP-43 intrabodies designed to restore normal TDP-43 function by reducing pathological TDP-43 aggregates in diseased neurons, aiming to halt disease progression in amyotrophic lateral sclerosis (ALS). Currently at pre-clinical stages.
  • MY012 An anti-ASC antibody targeting ASC, a crucial component of the inflammasome expressed by innate immune cells, to inhibit the propagation of inflammation triggered by ASC specks. Potential applications in inflammatory bowel disease (IBD) and neuroinflammation. Currently at pre-clinical stages.

Quantifiable outcome

  • MY006 Phase Ia completed with favorable safety and pharmacokinetic profiles; Safety Monitoring Committee recommended Phase Ib initiation
  • +1 more outcomes

Companies that use Mabylon

Customer profile

Segments5 records

Ideal customer profiles2 records

Mabylon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mabylon partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SciNeuro PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2021SciNeuro and Mabylon announced a Collaboration and License Agreement for the development of immunotherapy to fight ALS and FTLD (frontotemporal dementia), combining Mabylon's antibody expertise with SciNeuro's neurological disease focus.
  • Pfizer (Pfizer Ignite)coreStrategic or Co-development PartnerFor CMC and IND-enabling studies of the lead program MY006, Mabylon has collaborated with Pfizer through the Pfizer Ignite offering, an end-to-end service for selected biotech companies. This allowed Mabylon to leverage Pfizer's extensive therapeutic development expertise to speed the progression of the peanut allergy program.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Mabylon competitors and assessment

Company assessment

Direct peers

  • Numab Therapeutics: Swiss privately held biotech developing multi-specific antibody therapeutics; highly comparable as a fellow Schlieren/Zürich-area multi-specific antibody company whose lead asset (NM26) was acquired by J&J for $1.25B in 2024 — Mabylon's CMO Peter Lichtlen co-founded Numab.

Broad incumbents

  • Argenx: Late-stage immunology biotech developing antibody therapeutics for autoimmune diseases (e.g., VYVGART); comparable as a clinically validated antibody-focused immunology company and potential future competitor in allergy/inflammation.
  • UCB Pharma: Global biopharma with a major focus on immunology/autoimmune and neurology antibody therapeutics; Mabylon's CSO Niccolò Pengo previously worked on antibody therapeutics discovery at UCB.
  • Genentech (Roche): Global leader in monoclonal antibody therapeutics and immunology; highly relevant comparator given Mabylon's deep Roche DNA (Chairman Keller and Board member Haenggi are former Roche executives, and investors include former Roche management).
  • Vir Biotechnology: Clinical-stage immunology company leveraging human-derived antibody platforms (acquired HUMABS BioMed, Mabylon CEO's former company); comparable for its antibody platform approach and immunology focus, but operates at much larger scale.
  • Regeneron Pharmaceuticals: Large-cap biopharma with deep antibody discovery capabilities (VelocImmune platform) and marketed immunology assets (Dupixent); a relevant incumbent comparator for antibody platform reach and commercial scale in immunology.

Emerging players

  • BioInvent International: Swedish clinical-stage antibody biotech with a proprietary discovery platform targeting immuno-oncology and autoimmune diseases; comparable as an emerging clinical-stage antibody platform player, and Board member Thomas Hecht sits on BioInvent's board.
  • IgGenix: Clinical-stage biotech developing engineered allergen-specific IgG antibodies for food allergies; directly comparable as a passive-immunization antibody competitor in the peanut/food allergy space where Mabylon's MY006 is positioned.
  • MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing Nanobody® therapeutics for inflammatory diseases (e.g., hidradenitis suppurativa, psoriatic arthritis); comparable as a publicly listed emerging immunology-focused antibody developer.
  • Aiolos Bio: Clinical-stage biotech developing antibody therapeutics for respiratory and inflammatory diseases (formerly focused on severe asthma); comparable as an emerging antibody player in the I&I space.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mabylon social profiles

Digital presence

Mabylon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mabylon leadership team

Management profile

Number of profiles

Profiles11 records

Mabylon funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mabylon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabylon

What does Mabylon do?

Mabylon AG is a clinical-stage biotechnology company that discovers and engineers novel antibody therapeutics for allergies, inflammation, and neurological disorders. The company leverages a proprietary human-derived antibody discovery platform using B-cell screening and high-throughput expression to identify and clone monoclonal antibodies within two to three weeks, and develops these into multi-specific therapeutic candidates (MY006, MY010, MY011, MY001, MY012). The company advances candidates through clinical development in collaboration with pharmaceutical partners.

Is Mabylon a public or private company?

Mabylon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mabylon founded?

Mabylon was founded in 2015. It employs 11 to 50 people.

Where is Mabylon based?

Mabylon is headquartered in Schlieren, Switzerland, in the Europe region.

How does Mabylon make money?

One revenue line is on record: therapeutic antibody development and licensing.

Who are Mabylon's main competitors?

Numab Therapeutics is listed as a direct peer. Broad incumbents are Argenx, UCB Pharma, Genentech (Roche), Vir Biotechnology and Regeneron Pharmaceuticals. Emerging players are BioInvent International, IgGenix, MoonLake Immunotherapeutics and Aiolos Bio.

Does Mabylon have an API?

No public API is recorded for Mabylon.

What industry is Mabylon in?

Mabylon's product category is Biopharmaceuticals / Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPeer-Reviewed Publication In Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect Of Mabylon's Allergen-Neutralizing AntibodiesMabylon AG published a study in Clinical & Experimental Allergy showing its allergen-specific IgG4 antibodies redirect allergens toward tolerance-associated immune cells, reducing inflammation and promoting regulatory responses. The mechanism was observed in peanut and birch allergy models, supporting a disease-modifying effect. Clinical studies will determine if these effects translate to durable disease modification in patients.FinancialContent Business PagePeer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing AntibodiesMabylon AG published a study in Clinical & Experimental Allergy showing its allergen-specific IgG4 antibodies redirect allergens toward tolerance-associated immune cells. In peanut-allergy mouse models, the antibodies reduced mast-cell activation and prevented IgE increases during oral immunotherapy. The company plans to monitor disease-modification markers in its clinical programs.GlobeNewswirePeer-Reviewed Publication in Clinical & Experimental Allergy Reveals Potential Disease-Modifying Effect of Mabylon’s Allergen-Neutralizing AntibodiesMabylon AG published a study in Clinical & Experimental Allergy showing its allergen-specific IgG4 antibodies redirect allergens toward tolerance-associated immune cells, reducing inflammation and promoting regulatory responses. The mechanism was observed in peanut and birch allergy models, supporting a disease-modifying effect. Clinical studies will determine if these effects translate to durable disease modification in patients.startupticker.chSwiss biotechs progress across cardiology, oncology and allergy clinical programsFour biotechs reported clinical progress: HAYA Therapeutics dosed the first cohort in a Phase 1 cardiac fibrosis trial, Mabylon reported positive Phase 1a safety for its peanut allergy candidate, Molecular Partners published Phase 1 oncology data, and Anaveon sought partners after pivoting to immunology. Anaveon's ANV600 showed early signs of activity in a Phase 1 study.GlobeNewswireMabylon Reports Positive Phase Ia Results in MY006 Peanut Allergy Trial and Initiates Phase Ib Patient Part of the Study; Advances Tree Pollen Allergy Program MY010 toward Clinical DevelopmentMabylon AG reported preliminary positive Phase Ia data showing favorable safety and pharmacokinetic profiles for its lead candidate MY006 in an ongoing first-in-human peanut allergy trial, with the Safety Monitoring Committee recommending initiation of the Phase Ib patient part of the study. The company has also secured funding to advance both MY006 and its second program MY010 (targeting tree/Fagales pollen allergies) through subsequent stages of clinical development. MY006 is a subcutaneous multi-specific antibody designed to prevent allergic reactions including anaphylaxis in peanut-allergic individuals with only a few injections per year.EIN PresswirePeanut Allergy Treatment Market: Trends, Forecast, and Strategic Insights (2026–2033)The global peanut allergy treatment market is projected to grow from US$0.6 billion in 2026 to US$1.4 billion by 2033, a CAGR of 11.4%. Growth is driven by rising prevalence, advanced immunotherapies, and improved access, with North America leading and Asia Pacific fastest-growing.startupticker.chThree Swiss deep tech startups secure Eureka fundingAllegria Therapeutics, Mabylon, and Alivion secured EUR 2.8 million in non-dilutive funding from Eureka's Eurostars and Innowwide programs. Allegria's MastCURe project targets chronic urticaria, Mabylon's ASCEND advances an IBD therapy, and Alivion's study assesses a methanol detector in Brazil.GlobeNewswireMabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut AllergyMabylon AG has initiated a first-in-human Phase I clinical trial for MY006, a novel tri-specific monoclonal antibody designed for the prophylactic treatment of peanut allergy, with the first healthy volunteer now dosed in the U.S. study. The randomized, placebo-controlled trial will enroll up to 32 healthy volunteers in Part A and up to 16 peanut-allergic patients in Part B to assess safety, tolerability, pharmacokinetics, and immunogenicity of the antibody. The company received FDA IND clearance for the trial, marking Mabylon's transition to a clinical-stage biotech company, with MY006 designed to provide sustained protection through just 2-4 subcutaneous injections annually compared to existing therapies requiring frequent administration.startupticker.chBiotechs advance therapies against bacterial infections and peanut allergiesSwiss biotech company BioVersys has advanced its novel intravenous antibiotic candidate BV100 into a global Phase 3 registration study for drug-resistant Acinetobacter baumannii infections, with Phase 2 data showing a 50% relative reduction in all-cause mortality compared to best available therapy. Swiss biotech Mabylon has dosed its first healthy volunteer in a Phase 1 trial for MY006, a tri-specific monoclonal antibody for peanut allergy, following receipt of CHF 30 million in funding. Swiss biotech AC Immune has concluded its Phase 2 VacSYn trial of anti-alpha-synuclein immunotherapy ACI-7104.056 in early Parkinson's disease, with results suggesting the treatment could potentially slow disease progression.startupticker.chIn challenging times, strength equals resilienceSwiss start-ups saw record liquidations in the first half of 2025, with a higher proportion of financed companies. Three financing deals were reported, including Mabylon's CHF 30 million round, while customer and partner activity remains strong. International networking and upcoming events are highlighted as resilience factors.